1. Clinical Overview
A fixed-dose combination (FDC) medication used primarily for the management of painful diabetic peripheral neuropathy (DPN). Epalrestat is an aldose reductase inhibitor that targets the polyol pathway, a key contributor to diabetic nerve damage. Pregabalin is a gabapentinoid that modulates calcium channels to provide neuropathic pain relief. This combination offers a dual-pathway approach: addressing the underlying metabolic pathology and providing symptomatic pain control.
| Onset | Duration | Bioavailability |
|---|---|---|
| Pregabalin: Pain relief may begin within 1 week, with full effect often seen by 2-4 weeks. Epalrestat: Slower onset; biochemical effects on nerve sorbitol levels occur quickly, but clinical improvement in neuropathy symptoms may take 1-3 months of continuous therapy. | Pregabalin: Approximately 24 hours, supporting twice-daily dosing. Epalrestat: Its inhibitory effect on aldose reductase is sustained, requiring consistent daily dosing. | Pregabalin: >90% and is dose-linear. Epalrestat: Approximately 75-80%. |
2. Mechanism of Action
The combination works via two distinct mechanisms. Epalrestat inhibits the enzyme aldose reductase, which converts glucose to sorbitol in the polyol pathway. In hyperglycemia, sorbitol accumulation leads to osmotic stress, oxidative damage, and impaired nerve conduction velocity. By inhibiting this pathway, Epalrestat aims to slow the progression of diabetic neuropathy. Pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters (e.g., glutamate, substance P). This results in analgesic, anxiolytic, and anticonvulsant effects, providing symptomatic relief from neuropathic pain.
3. Indications & Uses
- Management of painful Diabetic Peripheral Neuropathy (DPN)
- Symptomatic treatment of neuropathic pain associated with diabetic neuropathy
4. Dosage & Administration
Adult Dosage: One tablet of Epalrestat 150mg + Pregabalin 75mg twice daily (after morning and evening meals). May be initiated at a lower dose (e.g., once daily) in sensitive patients to improve tolerability.
Administration: Administer orally with or immediately after meals to reduce potential gastrointestinal side effects and improve epalrestat tolerability. Tablet should be swallowed whole with a glass of water. Do not crush or chew.
5. Side Effects
Common side effects may include:
- Dizziness
- Somnolence (drowsiness)
- Peripheral edema (swelling of extremities)
- Weight gain
- Headache
- Dry mouth
- Fatigue
- Nausea
- Blurred vision (pregabalin)
- Constipation
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Potentiated sedation, dizziness, respiratory depression, and increased risk of accidents. | Major |
| Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., Ramipril, Enalapril) | Increased risk and severity of peripheral edema and angioedema. | Major |
| Thiazolidinediones (Pioglitazone, Rosiglitazone) | Additive risk of fluid retention, edema, and weight gain. | Moderate |
| Other Antidiabetic Agents (Insulin, Sulfonylureas) | Pregabalin may cause weight gain, potentially affecting glycemic control. No direct pharmacokinetic interaction. | Moderate |
| Loop Diuretics (Furosemide) | May reduce the efficacy of furosemide. Monitor for edema. | Moderate |
7. Patient Counselling
- DO take the medicine exactly as prescribed, usually twice daily after meals.
- DO NOT stop taking the medicine suddenly. Tapering under medical supervision is required to avoid withdrawal symptoms.
- DO NOT consume alcohol while on this medication.
- DO inform all your doctors and dentists that you are taking this medicine.
- DO monitor your weight regularly and report sudden increases or swelling in your feet/ankles.
- DO maintain strict control of your blood sugar levels with diet, exercise, and other antidiabetic medications.
8. Toxicology & Storage
Overdose: Signs are primarily related to pregabalin: Profound sedation, confusion, agitation, restlessness, severe dizziness, blurred vision, speech difficulty, diarrhea, and coma in massive overdose. Seizures have been reported. Epalrestat may contribute to GI upset and potential liver enzyme elevation.
Storage: Store below 30°C, in a cool, dry place. Protect from light and moisture. Keep the container tightly closed. Keep out of reach and sight of children. Do not use after the expiry date printed on the pack.